Shingles Vaccine Market Size & Growth Forecast 2026–2035, By Segments (Vaccine Type, Product), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Shingles Vaccine Market size was worth USD 5.42 Billion in 2025 and is expected to grow at a 15.2% CAGR between 2026 and 2035, reaching USD 22.31 Billion by 2035. The industry revenue for 2026 is assessed at USD 6.15 billion.
Get more details on this report
Request Free Sample ReportShingles Vaccine Market Intelligence Snapshot
Regional Market Dynamics
- North America leads with 60.39% share due to strong vaccine access, established adult immunization programs, reimbursement support, and pharmacy-based distribution channels enabling broad uptake.
- Asia Pacific is expanding at 17.02% CAGR driven by improving adult vaccination awareness, expanding healthcare access, and strengthening immunization infrastructure across large aging populations.
Segment Momentum
- Shingrix accounted for 89.43% of the market in 2025 due to its strong presence in vaccination programs, established prescribing practices, and well-developed commercial distribution and procurement channels.
- Live Attenuated Vaccine is the fastest-growing vaccine type as expanding regional immunization programs and favorable local procurement patterns create new opportunities for broader market adoption.
Market Expansion Drivers
- Expanding elderly population increasing demand for preventive shingles immunization programs globally.
- Advancements in recombinant vaccine technology improving efficacy and driving broader clinical adoption.
- Government-led adult vaccination initiatives expanding coverage in emerging healthcare systems and markets.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Major companies in the shingles vaccine market include GlaxoSmithKline plc (United Kingdom), Merck & Co. Inc. (United States), Pfizer Inc. (United States), SK bioscience Co. Ltd. (South Korea), Green Cross Corporation (South Korea), Geneone Life Science Inc. (South Korea), CanSino Biologics Inc. (China), Moderna Inc. (United States), Vaccitech plc (United Kingdom), BioNTech SE (Germany).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As the share of older adults rises, healthcare systems and providers are placing greater emphasis on prevention for age-associated infectious conditions, which is directly increasing demand for the shingles vaccine market. Shingles risk increases with age as immune function declines, so vaccination is increasingly being built into routine adult immunization schedules, geriatric care pathways, and pharmacy-based preventive health programs. This demographic shift also changes purchasing behavior at the system level, with hospitals, clinics, and public health agencies planning larger vaccine volumes and expanding outreach to aging populations, encouraging market growth through more consistent and recurring immunization demand.
Advancements in recombinant vaccine technology improving efficacy and driving broader clinical adoption
Improvements in recombinant vaccine technology are influencing market adoption by giving clinicians and immunization programs a stronger efficacy profile to justify adult shingles vaccination, especially for older and higher-risk populations. In the shingles vaccine market, better-performing recombinant formulations strengthen physician confidence, shape treatment recommendations, and support inclusion in clinical protocols where long-term protection and reduced disease burden are central considerations. That shift affects procurement and prescribing in practical terms, as healthcare providers and payers are more willing to support vaccines that align with preventive care objectives and deliver clearer value in adult immunization strategies.
Government-led adult vaccination initiatives expanding coverage in emerging healthcare systems and markets
Public-sector vaccination initiatives are increasing market presence by making adult immunization more visible, organized, and accessible in healthcare systems where shingles prevention has historically received limited attention. In the shingles vaccine market, government-backed programs often translate into formal recommendations, national procurement channels, reimbursement support, and integration into primary care delivery, all of which reduce access barriers for eligible adults. As emerging healthcare systems expand their preventive care infrastructure, these policies also influence provider behavior by normalizing adult vaccination as part of routine care rather than a discretionary intervention.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Expanding elderly population increasing demand for preventive shingles immunization programs globally | 2.60% | High | North America, Europe | High | Near Term |
| Advancements in recombinant vaccine technology improving efficacy and driving broader clinical adoption | 2.30% | High | North America, Asia Pacific | High | Mid Term |
| Government-led adult vaccination initiatives expanding coverage in emerging healthcare systems and markets | 2.00% | High | Asia Pacific, Latin America | Emerging | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held the leading regional share of the shingles vaccine market in 2025, accounting for 60.39% share. This position is underpinned by broad vaccine access through established healthcare delivery networks, strong adult immunization uptake, and routine use of preventive care in clinical practice. Market activity is further bolstered by high awareness of age-related disease prevention and the presence of structured reimbursement and pharmacy-based vaccination channels, which make adult shingles vaccination easier to recommend, dispense, and administer at scale.
Asia Pacific is projected to expand at a 17.02% CAGR over the forecast period in the shingles vaccine market, driven by improving adult vaccination awareness and wider healthcare access across major population centers. Growth is being accelerated by the practical expansion of immunization infrastructure, rising engagement with preventive healthcare, and increasing diagnosis and management of aging-related conditions through formal healthcare systems. As more patients enter organized care pathways and vaccine availability improves, adoption is gaining momentum across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Preventive Healthcare AlignmentGermany supports shingles vaccination through established preventive healthcare practices and recommendations for older adults. Healthcare providers continue promoting vaccination awareness while integrating immunization into routine preventive care and primary healthcare services.
France 🇫🇷
Healthcare Access ReinforcementFrance strengthens shingles vaccination through coordinated healthcare services and preventive care strategies for eligible adults. The market supports greater physician engagement and improved patient awareness to encourage broader vaccination participation.
Italy 🇮🇹
Community Immunization FocusItaly promotes shingles vaccination through regional healthcare programs and preventive immunization initiatives aimed at older adults. Healthcare organizations continue emphasizing patient education and accessible vaccination pathways to support consistent immunization practices.
Japan 🇯🇵
Aging Population ProtectionJapan prioritizes shingles vaccination as part of broader efforts to reduce disease burden among its aging population. Public health initiatives and healthcare providers continue encouraging vaccination uptake through improved awareness and preventive healthcare engagement.
South Korea 🇰🇷
Preventive Vaccination UptakeSouth Korea continues expanding shingles vaccination through preventive healthcare initiatives targeting adults at elevated risk. Healthcare providers focus on increasing awareness, improving patient education, and incorporating vaccination into broader adult immunization practices.
United States 🇺🇸
Adult Immunization ExpansionThe U.S. shingles vaccine market emphasizes expanding adult immunization through preventive healthcare initiatives and broad healthcare provider engagement. Vaccination programs increasingly focus on improving awareness among eligible adults while strengthening access through pharmacies and healthcare networks.
Segment Leadership and Growth Trends
Shingles Vaccine Market Share (%), Vaccine Type, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportRecombinant Vaccine held the dominant position in the shingles vaccine market in 2025, accounting for an 89.43% share. Its leadership is maintained through strong alignment with current immunization preferences, particularly where providers and public health programs prioritize broader adult use and dependable deployment across aging populations. Within the shingles vaccine market, this segment benefits from being the established choice in routine prevention pathways, which helps preserve purchasing continuity and physician familiarity.
Live Attenuated Vaccine is emerging as the fastest-growing segment in the shingles vaccine market as manufacturers and healthcare systems seek to expand access across varied regional product landscapes. Its momentum is underpinned by practical uptake opportunities in settings where existing vaccination infrastructure, product availability, or local procurement patterns favor this format over alternatives. Relative to more entrenched options, growth is being driven less by category dominance and more by incremental adoption in markets that are still broadening shingles immunization coverage.
Product Segment Analysis: Shingrix (Largest Segment) vs SKYZoster (Fastest-Growing Segment)
In 2025, Shingrix led the shingles vaccine market with an 89.43% share, reflecting its entrenched role in commercial supply channels and adult vaccination programs. The product maintains its leadership because demand in the market is concentrated around solutions already embedded in prescribing practices, distribution systems, and preventive care recommendations. This creates a practical advantage in ongoing procurement and administration, reinforcing Shingrix as the dominant product segment.
SKYZoster is the fastest-growing product segment in the shingles vaccine market, gaining traction as healthcare providers and regional buyers widen their product mix to support broader immunization reach. Its growth is tied to expansion opportunities where local availability, procurement flexibility, or market entry dynamics allow it to capture new demand more quickly than established products. Compared with the leading alternative, SKYZoster is benefiting from adoption in less saturated pockets of the market rather than from existing scale.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Vaccine Type | Recombinant Vaccine, Live Attenuated Vaccine | Recombinant Vaccine | Live Attenuated Vaccine |
| Product | Shingrix, Zostavax, SKYZoster | Shingrix | SKYZoster |
Competitive Landscape and Market Positioning
1. GlaxoSmithKline plc (United Kingdom)
2. Merck & Co. Inc. (United States)
3. Pfizer Inc. (United States)
4. SK bioscience Co. Ltd. (South Korea)
5. Green Cross Corporation (South Korea)
6. Geneone Life Science Inc. (South Korea)
7. CanSino Biologics Inc. (China)
8. Moderna Inc. (United States)
9. Vaccitech plc (United Kingdom)
10. BioNTech SE (Germany)
The shingles vaccine market is expanding due to increasing focus on preventive healthcare and aging population needs. The shingles vaccine market is witnessing innovation in next-generation immunization technologies. Continuous research collaboration is improving vaccine efficacy and protection duration.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Eli Lilly | Feb-26 | Eli Lilly executed definitive agreements to acquire Curevo, LimmaTech, and Vaccine Company in an aggregate transaction valued up to $3.8 billion. The multi-asset acquisition significantly expands Eli Lilly's pipeline across viral and bacterial pathogens, explicitly integrating Curevo's specialized assets to accelerate corporate entry and research capabilities within the next-generation shingles prevention market. |
| Sanofi | Feb-26 | Sanofi reached an agreement to acquire Dynavax Technologies for approximately $2.2 billion, absorbing its commercial immunization portfolio alongside Z-1018, an investigational Phase 1/2 shingles vaccine candidate. The strategic transaction accelerates Sanofi's competitive positioning in adult vaccinology, providing a direct pipeline entry point to challenge established market leaders in herpes zoster prevention. |
| Curevo Vaccine | Feb-26 | Curevo Vaccine secured $110 million in Series B venture financing led by Medicxi, with co-investment from OrbiMed, HBM Healthcare Investments, and Sanofi Ventures. The capital infusion is strategically earmarked to fund the advanced clinical expansion and regulatory development of amezosvatein, the company's leading investigational shingles vaccine candidate. |
| AIM Vaccine Co., Ltd. | Mar-25 | AIM Vaccine Co., Ltd. secured investigational clinical trial approval from the U.S. Food and Drug Administration for its independently developed mRNA shingles vaccine candidate. The regulatory clearance allows the company to initiate human trials within the United States, marking a critical operational milestone for mRNA platform validation in the competitive shingles prevention landscape. |
| Dynavax Technologies Corporation | Jun-24 | Dynavax Technologies Corporation initiated patient dosing in its Phase 1/2 clinical trial evaluating the safety, tolerability, and immunogenicity of its investigational shingles vaccine candidate, Z-1018. This clinical milestone marks the early-stage commercial development of an alternative adjuvant-based therapeutic regimen designed to prevent herpes zoster reactivations. |
| EuBiologics | Feb-26 | EuBiologics disclosed positive interim data from its Phase 1 clinical trial of the EuHZV shingles vaccine candidate, demonstrating safety and immunogenicity profiles comparable to an active control vaccine. The clinical results establish a viable baseline to advance the candidate into larger efficacy trials, positioning the firm to contest the global shingles market. |
| SK bioscience | Jan-23 | SK bioscience obtained Biologics License Application approval from Malaysia’s National Pharmaceutical Regulatory Agency for its shingles vaccine, SKYZoster. This regulatory clearance marks the product’s second international market entry following its initial approval in Thailand, expanding the manufacturer's geographic footprint and commercial distribution network across Southeast Asia. |
| GlaxoSmithKline (GSK) | Feb-26 | GlaxoSmithKline expanded the commercial footprint of its recombinant zoster vaccine, Shingrix, by launching the product in Malaysia. The geographic expansion broadens preventative healthcare access for adults aged 50 and older or those at elevated risk, reinforcing the company's dominant global market share in shingles prevention. |
| GlaxoSmithKline (GSK) | Mar-25 | GlaxoSmithKline formed a specialized research coalition with the UK Dementia Research Institute and Health Data Research UK to execute a population-level health data study. The scientific initiative investigates a potential statistical correlation between Shingrix vaccination and reduced dementia incidence, potentially generating unique clinical differentiation and a new marketing paradigm for the asset. |
| SK bioscience | Feb-26 | SK bioscience reorganized its operational focus to scale its commercial shingles vaccine portfolio, aiming to capture global market share unaddressed due to recent competitor product withdrawals. The defensive repositioning optimizes supply chain and manufacturing capabilities to align with rising seasonal demands for adult immunizations. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Shingles Vaccine Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Shingles Vaccine Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow large is the shingles vaccine market?
What is the expected industry size of shingles vaccine by 2035?
How is population aging shaping procurement strategies in the shingles vaccine market?
Why are recombinant vaccine advancements accelerating adoption in the shingles vaccine market?
Why does Shingrix dominate the shingles vaccine market?
Which vaccine type is growing fastest in the shingles vaccine market?
Why does North America dominate the shingles vaccine market?
What is driving Asia Pacific’s growth in shingles vaccine adoption?
Who holds a significant market share in the shingles vaccine landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization